Spironolactone Treatment and Clinical Outcomes in Patients With Systolic Dysfunction and Mild Heart Failure Symptoms: A Retrospective Analysis

Journal of Cardiac Failure

Volumn 12, Issue 4, 2006, Pages 250-256

  Baliga, Ragavendra R ^a   Ranganna, Prathiba ^a   Pitt, Bertram ^a   Koelling, Todd M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aldosterone antagonists; Left ventricular systolic dysfunction; Mortality; Patient readmission

Indexed keywords

SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; DEATH; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG USE; FEMALE; FOLLOW UP; HEART ASSIST DEVICE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART TRANSPLANTATION; HOSPITAL READMISSION; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SYMPTOM;

ADULT; AGED; AGED, 80 AND OVER; ALDOSTERONE ANTAGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SODIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33646167293     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.01.013     Document Type: Article

References (20)

1. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
2. Hunt S.A., Baker D.W., Chin M.H., Cinquegrani M.P., Feldman A.M., Francis G.S., et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 38 (2001) 2101-2113
3. Swedberg K., Eneroth P., Kjekshus J., and Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 82 (1990) 1730-1736
4. Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation 108 (2003) 1790-1794
5. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
6. The MERIT-HF Investigators. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353 (1999) 2001-2007
7. Tamirisa K.P., Aaronson K.D., and Koelling T.M. Spironolactone induced renal insufficiency and hyperkalemia in heart failure patients. Am Heart J 148 (2004) 971-978
8. Rosenbaum P.R., and Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 70 (1983) 41-55
9. Bozkurt B., Agoston I., and Knowlton A.A. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol 41 (2003) 211-214
10. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med 345 (2001) 1689-1697
11. White W.B., Duprez D., St Hillaire R., Krause S., Roniker B., Kuse-Hamilton J., et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 41 (2003) 1021-1026
12. Williams G.H., Burgess E., Kolloch R.E., Ruilope L.M., Niegowska J., Kipnes M.S., et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93 (2004) 990-996
13. Grandi A.M., Imperiale D., Santillo R., Barlocco E., Bertolini A., Guasti L., et al. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 40 (2002) 647-652
14. Rachmani R., Slavachevsky I., Amit M., Levi Z., Kedar Y., Berla M., et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabetic Med 21 (2004) 471-475
15. Sato A., Hayashi K., Naruse M., and Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41 (2003) 64-68
16. Satoh M., Nakamura M., Saitoh H., Satoh H., Akatsu T., Iwasaka J., et al. Aldosterone synthase (cyp11b2) expression and myocardial fibrosis in the failing human heart. Clin Sci 102 (2002) 381-386
17. Pitt B., Stier Jr. C.T., and Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin-Angiotensin-Aldosterone Sys 4 (2003) 164-168
18. Macdonald J.E., Kennedy N., and Struthers A.D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90 (2004) 765-770
19. Ramires F.J., Mansur A., Coelho O., Maranhao M., Gruppi C.J., Mady C., et al. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 85 (2000) 1207-1211
20. Juurlink D.N., Mamdani M.M., Lee D.S., Kopp A., Austin P.C., Laupacis A., et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351 (2004) 543-551